Jiangsu Cancer Institute & Hospital

This phase II trial is testing a combination of three drugs—QL1706 (an immunotherapy), anlotinib (a targeted therapy), and nab-paclitaxel (chemotherapy)—as a first treatment for advanced triple-negative breast cancer. The study will enroll 34 women and aims to see if the combo ca…

This study is testing whether a chemotherapy pill (oral paclitaxel) combined with radiation can safely treat advanced esophageal cancer that cannot be removed by surgery. It is for people aged 70 or older, or those who cannot tolerate standard IV chemo. The goal is to control the…

This phase 2 trial is testing a combination of two immune-boosting antibodies (iparomlimab and tuvonralimab) plus chemotherapy for people with stage III non-small cell lung cancer that cannot be removed by surgery. The study will enroll 33 adults who have not had prior treatment.…

This phase 2 study is testing a combination of three drugs (disitamab vedotin, carboplatin, and bevacizumab) as first treatment and ongoing therapy for women with a specific type of advanced ovarian cancer that has a protein called HER2 and lacks a repair deficiency (HRD-negative…